title: The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
abstract: Inhibition of Ras-dependent signaling and of oncogenic Ras function by farnesyl transferase inhibitors that block Ras membrane anchorage is limited due to alternative prenylation of Ras. Here we demonstrate that inhibition of the Ras-dependent Raf-1-MAPK (mitogen activated protein kinase) cascade is achieved by S-farnesylthiosalicylic acid (FTS) which affects Ras membrane association but not Ras farnesylation. FTS interferes with the activation of Raf-1 and MAPK and inhibits DNA synthesis in Ras-transformed EJ cells at concentrations similar to those at which it inhibits EJ cell growth (5-25 microM). FTS also inhibits MAPK activity and DNA synthesis stimulated by serum, EGF or thrombin in serum-starved untransformed Rat-1 cells, demonstrating the generality of its effects on Ras-dependent signaling. The effects of FTS on MAPK activity developed relatively rapidly (within 2-6 h) consistent with its rapid effect on Ras membrane anchorage. FTS represents a new class of Ras antagonists that may be useful for the inhibition of various types of oncogenic Ras isoforms independently of their prenylation.
authors.affiliation: Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Gana-Weisz
authors.forename: R
authors.initials: R
authors.lastname: Haklai
authors.forename: D
authors.initials: D
authors.lastname: Marciano
authors.forename: Y
authors.initials: Y
authors.lastname: Egozi
authors.forename: G
authors.initials: G
authors.lastname: Ben-Baruch
authors.forename: Y
authors.initials: Y
authors.lastname: Kloog
mesh_terms: D000818:Animals; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors*; D002460:Cell Line; D004261:DNA Replication / Q000187:drug effects; D004273:DNA, Neoplasm / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005204:Farnesol / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D019908:Proto-Oncogene Proteins c-raf; D051381:Rats; D015682:Retroviridae Proteins, Oncogenic / Q000378:metabolism; D012459:Salicylates / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors; D013936:Thymidine / Q000378:metabolism; D014407:Tumor Cells, Cultured; D018631:ras Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D015682:Retroviridae Proteins, Oncogenic; D012459:Salicylates; C093323:farnesylthiosalicylic acid; D005204:Farnesol; D004815:Epidermal Growth Factor; D019908:Proto-Oncogene Proteins c-raf; C107753:proto-oncogene protein v-RAF1, pig; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D013917:Thrombin; D018631:ras Proteins; D013936:Thymidine